1. Inicio
  2. Publicaciones
  3. Cefto Real-Life Study: Real-World Data on the Use of Ceftobiprole in a Multicenter Spanish Cohort.

Cefto Real-Life Study: Real-World Data on the Use of Ceftobiprole in a Multicenter Spanish Cohort.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Hidalgo-Tenorio, Carmen
  • Pitto-Robles, Ines
  • Arnés García D
  • de Novales FJM
  • Morata, Laura
  • de Pablo, Olga Bravo
  • López de Medrano VA
  • Vizcarra, Pilar
  • Lora-Tamayo, Jaime
  • Arnáiz García A
  • Núñez LM
  • Seco MPR
  • Sadyrbaeva-Dolgova, Svetlana

Grupos

Abstract

BACKGROUND: Ceftobiprole is a fifth-generation cephalosporin that has been approved in Europe solely for the treatment of community-acquired and nosocomial pneumonia. The objective was to analyze the use of ceftobiprole medocaril (Cefto-M) in Spanish clinical practice in patients with infections in hospital or outpatient parenteral antimicrobial therapy (OPAT). METHODS: This retrospective, observational, multicenter study included patients treated from 1 September 2021 to 31 December 2022. RESULTS: A total of 249 individuals were enrolled, aged 66.6 ± 15.4 years, of whom 59.4% were male with a Charlson index of four (IQR 2-6), 13.7% had COVID-19, and 4.8% were in an intensive care unit (ICU). The most frequent type of infection was respiratory (55.8%), followed by skin and soft tissue infection (21.7%). Cefto-M was administered to 67.9% of the patients as an empirical treatment, in which was administered as monotherapy for 7 days (5-10) in 53.8% of cases. The infection-related mortality was 11.2%. The highest mortality rates were identified for ventilator-associated pneumonia (40%) and infections due to methicillin-resistant Staphylococus aureus (20.8%) and Pseudomonas aeruginosa (16.1%). The mortality-related factors were age (OR: 1.1, 95%CI (1.04-1.16)), ICU admission (OR: 42.02, 95%CI (4.49-393.4)), and sepsis/septic shock (OR: 2.94, 95%CI (1.01-8.54)). CONCLUSIONS: In real life, Cefto-M is a safe antibiotic, comprising only half of prescriptions for respiratory infections, that is mainly administered as rescue therapy in pluripathological patients with severe infectious diseases.

Datos de la publicación

ISSN/ISSNe:
2079-6382, 2079-6382

Antibiotics-Basel  MDPI

Tipo:
Article
Páginas:
-
PubMed:
37508314
Factor de Impacto:
0,785 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 14

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • OPAT; ceftobiprole; older; real-world data; sepsis

Campos de Estudio

Compartir